The present invention provides an epitope peptide derived from URLC10 and having a cytotoxic T-cell induction ability. The present invention also provides: a polynucleotide for coding the peptide； an antigen-presenting cell presenting the peptide, and a cytotoxic T-cell for targeting the peptide； and a method for inducing the antigen-presenting cell or the CTL. The present invention further provides a composition containing these as an active ingredient thereof, and a pharmaceutical composition. The present invention also provides a method for treating and/or preventing cancer, and/or preventing a relapse of cancer after surgery, by using the peptide, polynucleotide, antigen-presenting cell, cytotoxic T-cell, or pharmaceutical composition. Furthermore, the present invention provides a method for inducing an immune response against cancer.本發明提供具有細胞傷害性T細胞誘導能力之來自URLC10的抗原決定位胜肽。本發明並提供編碼為該胜肽之多核苷酸、呈現該胜肽之抗原呈現細胞及誘導以該胜肽為標靶之細胞傷害性T細胞、及該抗原呈現細胞或該CTL之方法。本發明更包含以該等作為有效成分之組合物及藥學組合物。本發明更提供使用本發明之胜肽、多核苷酸、抗原呈現細胞、細胞傷害性T細胞、或本發明之藥學組合物來治療及/或預防癌，及/或預發術後之癌再發之方法。又，提供誘導對於癌之免疫應答之方法。
